The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    March 2020

  • Pages
    317

  • View Count
    5072

Example Insights

Pharmaceutical-Continuous-Manufacturing Market-Context Continuous-Manufacturing-Market-Drug-Manufacturing Continuous-Manufacturing-Market-List-of-companies Continuous-Manufacturing-Market-Types-of-geography
Continuous-Manufacturing-Market-Distribution-by-location Pharmaceutical-Continuous-Manufacturing-Patent-analysis Pharmaceutical-Continuous-Manufacturing-Grant-analysis Continuous-Manufacturing-Market-Recent-partnership
Continuous-Manufacturing-Market-Capacity Continuous-Manufacturing-Market-Stakeholders Continuous-Manufacturing-Market-Forecast  

 

Overview

Recent advances in the manufacturing technologies have prompted pharmaceutical companies to shift from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing.  Continuous manufacturing, also known as continuous flow chemistry, is an advanced manufacturing technology, which drives operations in a continuous manner (24×7) in one facility, without hold times.  The concept was first described in the 1700s, in relation to the production of pig iron in blast furnaces.  Since then, the technique has been used in various industries, including automotive, food and beverage, oil refining, chemicals, pulp and paper, electronics, metal smelting, steel making, and waste-water treatment industries. ,   In recent years, continuous manufacturing is becoming popular within the biopharmaceutical industry as well, having captured the attention of many big pharma players, as well as leading contract manufacturing organizations (CMOs). The key benefits associated with the adoption of continuous manufacturing technology include reduction in manufacturing cost (by 15-30%), reduction in manpower (by 50-70%), less product deviation (by 50%), smaller footprint requirement (by 50-70%), reduction in power consumption (by 40%) and faster scale up.  Specifically for biologics, continuous manufacturing, through upstream perfusion, is already a well-established field; this can be justified by the fact that, till now, more than 20 biologics manufactured based on this approach have been approved by the FDA.  On the other hand, for oral solid dosage (OSD) forms and small molecules, continuous processing technology presents a versatile and beneficial manufacturing approach. Since 2015, six orally administrable drugs, manufactured using the continuous technique, have been approved by the FDA; these are TRIKAFTA® (Vertex Pharmaceuticals, 2019), DAURISMO™ (Pfizer, 2018), SYMDEKO® (Vertex Pharmaceuticals, 2018), VERZENIO® (Eli Lilly, 2017), PREZISTA® (Johnson & Johnson, 2016) and ORKAMBI® (Vertex Pharmaceuticals, 2015). ,  , ,  

There are several technology providers / equipment suppliers, offering the necessary technologies and equipment for continuous manufacturing, such as continuous flow reactors (plug flow reactors, continuous stirred tank reactors (CSTR) and microreactors), continuous granulators, continuous coaters, continuous mixers / blenders, continuous chromatography equipment, continuous dryers and process analytical technologies (PAT). In addition, many companies have made heavy investments in order to install this technology and expand their facilities and capabilities in this regard. Moreover, innovators engaged in this field have received significant support in the form of grants from various administering institutes and incentives from key regulatory agencies as well.  Despite the challenges associated with the adoption of this technology (such as cost of equipment, process development restrictions, manufacturing of a new facility and maintenance of the equipment), we believe that the opportunity for both technology developers and manufacturers / users engaged in this domain is likely to grow in the foreseen future. In fact, the ongoing COVID-19 crisis is expected to accelerate the industry’s shift towards advanced manufacturing platforms including continuous manufacturing.

Scope of the Report

The ‘Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030’ report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (biologic and small molecule), type of continuous manufacturing related service(s) offered (process development, API manufacturing, intermediate manufacturing, drug product manufacturing, and packaging and fill / finish),  type of dosage form (solid and liquid), and installed capacity and batch size (if available). 
  • Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market in North America, Europe and Asia-Pacific. Each profile features an overview of the company, its financial information (if available), information related to its service portfolio, continuous manufacturing capabilities and facilities, recent developments and an informed future outlook.
  • An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an agreement, the type of partnership (research agreements, facility development / establishment agreements, technology enhancement agreements, service alliances, process development agreements, manufacturing agreements and other relevant agreements), scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid). It also provides the regional distribution of the collaborations.
  • An analysis of the expansions related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an expansion and the type of expansion (facility / plant expansion, technology installation, technology enhancement and service expansion), geographical location of the facility, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).
  • An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites). The study examines the distribution of capacity, based on the type of drug molecule (biologic and small molecule), company size (small-sized, mid-sized and large), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location  of manufacturing facilities (North America, Europe and Asia-Pacific).
  • A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019, highlighting multiple parameters, such as year of award, activity code, grant amount, focus area, support period, popular recipient organizations, type of recipient organization, funding institute center, funding mechanism and prominent program officers. 
  • An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019. It includes information on key parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of the size of intellectual property portfolio). It also features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach), as well as a patent benchmarking and a detailed valuation analysis.
  • Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects. 
  • A review of the companies offering modular facilities / modular cleanrooms, with information on their geographical location (North America, Europe, Asia-Pacific and rest of the world), year of establishment, company size (small-sized, mid-sized or large) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on the recent projects undertaken / executed by the companies providing modular facilities.
  • A case study of the companies offering technologies / equipment (continuous blenders and mixers, continuous granulators, continuous dryers, continuous compressors, continuous coaters, flow reactors / bioreactors, continuous filtration, distillation and centrifugation equipment, continuous chromatography, PAT technology and other technologies) that can potentially be used in a continuous manufacturing process, providing information on the geographical location of potential stakeholders and the type of technology / equipment provided.
  • A case study on the roadmap for the adoption of continuous manufacturing technique, discussing different strategies that can be followed by the company in order to adopt this technology or transition from batch manufacturing to continuous manufacturing.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as overall market of the currently approved drugs based on continuous manufacturing, cost of goods sold and direct manufacturing cost, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] purpose of manufacturing (in-house and contract services) [B] scale of operation (preclinical, clinical and commercial), [C] type of drug molecule (small molecule and biologic), [D] type of continuous manufacturing related service (API manufacturing and  end product manufacturing), [E] type of dosage form (solid and liquid) and [F] key geographical regions (North America, Europe and Asia-Pacific). To account for the uncertainties associated with the continuous manufacturing of pharmaceuticals and biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Andrea Adamo (Founder and Chief Executive Officer, Zaiput Flow technologies)
  • Bayan Takizawa (Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals)
  • Eric Fang (Chief Scientific Officer, Snapdragon Chemistry)
  • Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences)
  • Nick Thomson (Senior Director Chemical Research and Development, Pfizer)
  • Ian Houson (Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Recent Developments

  • Quartic.ai and Bright Path Laboratories recently inked and agreement to jointly develop an artificial intelligence (AI) technology platform designed for continuous manufacturing of active pharmaceutical ingredients (APIs) and other small-molecule drugs (Source)
  • The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that it is funding 14 new projects in technology, workforce development, and the Global Health Fund initiative, amounting to approximately $10 million (Source)
     

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the pharmaceutical and biopharmaceutical continuous manufacturing market in the short to mid-term and long term.

Chapter 3 provides a general introduction to continuous flow chemistry. The chapter also includes the historical evolution of continuous manufacturing in the pharmaceutical industry. It features a brief overview of the regulatory landscape, the early adopters of this technology, advantages and key challenges associated with this technique. The chapter also discusses the future perspective of the pharmaceutical and biopharmaceutical continuous manufacturing market.

Chapter 4 provides a comprehensive overview of the market landscape of continuous manufacturing. The chapter features information on year of establishment, company size, purpose of manufacturing (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (biologic and small molecule), type of continuous manufacturing related service offered (process development, API manufacturing, intermediate manufacturing, drug product manufacturing, and packaging and fill / finish),  type of dosage form offered (solid and liquid), and installed capacity and batch size (if available). 

Chapter 5 features detailed profiles of some of the key contract manufacturers that are active in the pharmaceutical and biopharmaceutical continuous manufacturing market in North America. Each profile presents a brief overview of the company, its overall contract service offerings, continuous manufacturing capabilities and facilities, recent developments and future outlook.

Chapter 6 features detailed profiles of some of the key contract manufacturers that are active in the pharmaceutical and biopharmaceutical continuous manufacturing market in Europe. Each profile presents a brief overview of the company, its overall contract service offerings, continuous manufacturing capabilities and facilities, recent developments and future outlook.

Chapter 7 features detailed profiles of some of the key contract manufacturers   that are active in the pharmaceutical and biopharmaceutical continuous manufacturing market in Asia-Pacific. Each profile presents a brief overview of the company, its overall contract service offerings, continuous manufacturing capabilities and facilities, recent developments and future outlook.

Chapter 8 features an elaborate discussion and analysis of the various collaborations that have taken place in this market, since 2013. Further, the partnership activities in this domain have been analyzed on the basis of year of an agreement, the type of partnership (research agreements, facility development / establishment agreements, technology enhancement agreements, service alliances, process development agreements, manufacturing agreements and other relevant agreements) and regional distribution of the collaborations. The instances that we came across were analyzed based on various parameters including, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).

Chapter 9 features an elaborate discussion and analysis of the various expansions that have taken place in this market, since 2013. Further, the expansion activities in this domain have been analyzed on the basis of year of an expansion and the type of expansion (facility / plant expansion, technology installation, technology enhancement and service expansion). The instances that we came across were analyzed based on various parameters, including, geographical location of the facility, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).

Chapter 10 features an estimate of the overall, installed capacity for manufacturing drug substances and drug products based on information reported by industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of type of drug molecule (biologic and small molecule), company size (small-sized, mid-sized and large), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific), location  of manufacturing facilities (North America, Europe and Asia-Pacific).

Chapter 11 provides information on the various grants that were awarded to research institutes conducting projects related to continuous manufacturing, between 2014 and 2019. The analysis also highlights important parameters associated with grants, such as year of award, activity code, grant amount, focus area, support period, popular recipient organizations, type of recipient organization, funding institute center, funding mechanism and prominent program officers. 

Chapter 12 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to continuous manufacturing. For this analysis, we looked at the patents that have been published by various players, till 2019. The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, assigned CPC symbol, emerging focus area, type of applicant and leading industry / academic players (in terms of size of intellectual property portfolio). It features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 13 highlights initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects. 

Chapter 14 features a review of the companies offering modular facility / modular cleanroom with information on their geographical location (North America, Europe, Asia-Pacific and rest of the world), establishment year, size (small-sized, mid-sized or large) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on the recent projects undertaken by these companies.

Chapter 15 presents a case study on the companies offering technologies / equipment (continuous blenders and mixers, continuous granulators, continuous compressors, continuous coaters, continuous dryers, flow reactors / bioreactors, continuous filtration, distillation and centrifugation equipment, continuous chromatography, PAT technology and other technologies) that can potentially be used in a continuous manner, providing information on the geographical location of potential stakeholders and the type of technology / equipment provided.

Chapter 16 a case study on the roadmap for the adoption of continuous manufacturing technique, discussing different strategies that can be followed by the company in order to adopt this technology or transition from batch manufacturing to continuous manufacturing.

Chapter 17 presents a comprehensive market forecast analysis, highlighting the likely growth of the pharmaceutical and biopharmaceutical continuous manufacturing market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] purpose of manufacturing (in-house and contract services) [B] scale of operation (preclinical, clinical and commercial), [C] type of drug molecule (small molecule and biologic), [D] type of continuous manufacturing related service (API manufacturing and  end product manufacturing) and [E] type of dosage form (solid and liquid) and [F] key geographical regions (North America, Europe and Asia-Pacific). 

Chapter 18 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 19 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Andrea Adamo (Founder and Chief Executive Officer, Zaiput Flow technologies), Bayan Takizawa (Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals), Eric Fang (Chief Scientific Officer, Snapdragon Chemistry), Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences), Nick Thomson (Senior Director Chemical Research and Development, Pfizer) and Ian Houson (Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde).

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 21 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Continuous Manufacturing 
3.3. Continuous Manufacturing in the Pharmaceutical Industry
3.3.1. Regulatory Landscape
3.3.2. Early Adopters of Continuous Manufacturing
3.3.3. Anticipated Shift to Continuous Manufacturing
3.3.4. Advantages of Continuous Manufacturing
3.3.5. Key Challenges Associated with Continuous Manufacturing
3.3.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Companies with Expertise in Continuous Manufacturing: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose of Manufacturing
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Location of Headquarters
4.2.6. Analysis by Location of Continuous Manufacturing Facilities
4.2.7. Analysis by Type of Drug Molecule
4.2.8. Analysis by Type of Continuous Manufacturing Related Service
4.2.9. Analysis by Type of Dosage Form
4.2.10. Heat Map: Analysis by Company Size and Location of Headquarters
4.2.11. Information on Production Capacity
4.2.12. Logo Landscape: Analysis by Year of Establishment and Company Size  
4.2.13. Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form
4.2.14. Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

5. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES
5.1. Chapter Overview
5.2. AbbVie Contract Manufacturing
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Service Portfolio
5.2.4. Continuous Manufacturing Capabilities and Facilities
5.2.5. Recent Developments and Future Outlook

5.3. Cambrex
5.3.1. Company Overview
5.3.2. Financial Information
5.3.4. Service Portfolio
5.3.5. Continuous Manufacturing Capabilities and Facilities
5.3.6. Recent Developments and Future Outlook

5.4. Patheon (acquired by Thermo Fisher Scientific)
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Service Portfolio
5.4.4. Continuous Manufacturing Capabilities and Facilities
5.4.5. Recent Developments and Future Outlook

5.5. SK biotek
5.5.1. Company Overview
5.5.2. Service Portfolio
5.5.3. Continuous Manufacturing Capabilities and Facilities
5.5.4. Recent Developments and Future Outlook

6. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES
6.1. Chapter Overview
6.2. Ajinomoto Bio-Pharma Service
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Continuous Manufacturing Capabilities and Facilities
6.2.5. Recent Developments and Future Outlook 

6.3. Almac Group
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Continuous Manufacturing Capabilities and Facilities
6.3.4. Recent Developments and Future Outlook

6.4. Boehringer Ingelheim BioXcellence™
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Service Portfolio
6.4.4. Continuous Manufacturing Capabilities and Facilities
6.4.5. Recent Developments and Future Outlook

6.5. CordonPharma
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Continuous Manufacturing Capabilities and Facilities
6.5.4. Recent Developments and Future Outlook

6.6. Hovione
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Continuous Manufacturing Capabilities and Facilities
6.6.4. Recent Developments and Future Outlook

6.7. Lonza
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Service Portfolio
6.7.4. Continuous Manufacturing Capabilities and Facilities
6.7.5. Recent Developments and Future Outlook

7. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES
7.1. Chapter Overview
7.2. Kaneka
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Service Portfolio
7.2.4. Continuous Manufacturing Capabilities and Facilities
7.2.5. Recent Developments and Future Outlook 

7.3. WuXi AppTec
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Service Portfolio
7.3.4. Continuous Manufacturing Capabilities and Facilities
7.3.5. Recent Developments and Future Outlook

8. RECENT PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Scale of Operation
8.3.4. Analysis by Type of Drug Molecule
8.3.5. Analysis by Type of Continuous Manufacturing Related Service
8.3.6. Analysis by Type of Dosage Form
8.3.7. Most Active Players: Analysis by Number of Partnerships

8.3.8. Regional Analysis
8.3.8.1. Intercontinental and Intracontinental Agreements

9. RECENT EXPANSIONS
9.1. Chapter Overview
9.2. Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Expanded Scale of Expansion
9.2.4. Analysis by Type of Drug Molecule
9.2.5. Analysis by Type of Continuous Manufacturing Related Service
9.2.6. Analysis by Type of Dosage Form
9.2.7. Most Active Players: Analysis by Number of Expansions

9.2.8. Regional Analysis
9.2.8.1. Analysis by Location of Expansion Project

10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodology
10.3. Global, Continuous Manufacturing Capacity for Small Molecule APIs
10.3.1. Analysis by Company Size
10.3.2. Analysis by Purpose of Manufacturing
10.3.3. Analysis by Scale of Operation 
10.3.4. Analysis by Location of Headquarters
10.3.4. Analysis by Location of Continuous Manufacturing Facilities
 
10.4. Global, Continuous Manufacturing Capacity for Small Molecule End Products
10.4.1. Analysis by Company Size
10.4.2. Analysis by Purpose of Manufacturing
10.4.3. Analysis by Scale of Operation
10.4.4. Analysis by Location of Headquarters
10.4.5. Analysis by Location of Continuous Manufacturing Facilities

10.5. Global, Continuous Manufacturing Capacity for Biologic
10.5.1. Analysis by Company Size
10.5.2. Analysis by Purpose of Manufacturing
10.5.3. Analysis by Scale of Operation
10.5.4. Analysis by Location of Headquarters
10.5.5. Analysis by Location of Continuous Manufacturing Facilities

11. ACADEMIC GRANT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Continuous Manufacturing: List of Academic Grants
11.3.1. Analysis by Number of Grants
11.3.2. Analysis by Activity Code
11.3.3. Analysis by Grant Amount
11.3.4. Analysis by Focus Area
11.3.5. Analysis by Support Period
11.3.6 Popular Recipient Organizations: Analysis by Number of Grants
11.3.7 Analysis by Type of Recipient Organization
11.3.8. Analysis by Funding Institute Center
11.3.9. Analysis by Funding Mechanism
11.3.10. Prominent Program Officers: Analysis by Number of Grants

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Continuous Manufacturing: Patent Analysis
12.3.1. Analysis by Publication Year
12.3.2. Analysis by Geography
12.3.3. Analysis by CPC Symbols
12.3.4. Emerging Focus Areas
12.3.5. Analysis by Type of Applicant
12.3.6. Leading Players: Analysis by Number of Patents
12.3.7. Continuous Manufacturing: Three-Dimensional Bubble Analysis
12.3.8. Continuous Manufacturing: Patent Valuation Analysis
12.3.8.1. Leading Patents: Information by Number of Citations

13. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES
13.1. Chapter Overview
13.2. Continuous Manufacturing Initiatives of Leading Companies
13.2.1. AbbVie
13.2.1.1. Partnered Initiatives 
13.2.1.2. In-House Initiatives

13.2.2. Amgen
13.2.2.1. Partnered Initiatives
13.2.2.2. In-House Initiatives

13.2.3. Bristol-Myers Squibb
13.2.3.1. Partnered Initiatives
13.2.3.2. In-House Initiatives

13.2.4. GlaxoSmithKline
13.2.4.1. Partnered Initiatives
13.2.4.2. In-House Initiatives

13.2.5. Merck
13.2.5.1. Partnered Initiatives
13.2.5.2. In-House Initiatives

13.2.6. Novartis
13.2.6.1. Partnered Initiatives
13.2.6.2. In-House Initiatives

13.2.7. Pfizer
13.2.7.1. Partnered Initiatives
13.2.7.2. In-House Initiatives

13.2.8. Roche
13.2.8.1. Partnered Initiatives
13.2.8.2. In-House Initiatives 
13.2.9. Sanofi
13.2.9.1. Partnered Initiatives
13.2.9.2. In-House Initiatives 

14. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY
14.1. Chapter Overview
14.2. Historical Background
14.3. Concept of Modularization
14.3.1. Types of Modules
14.3.2. Modular Construction Process

14.4. Modular Construction in the Pharmaceutical Industry
14.4.1. Advantages of Modular Construction in the Pharmaceutical Industry

14.5. Modular Facility Manufacturers
14.5.1. Distribution by Industry Served 
14.5.2. Distribution by Geography 
14.5.3. Modular Projects Executed / Undertaken

14.6. Modular Pharmaceutical Cleanrooms
14.6.1. Cleanroom Classification and Current Standards
14.6.2. Advantages of Modular Cleanrooms
14.6.3. Regulations and Standards Concerning Modular Cleanroom Construction

14.7. Modular Cleanroom Providers
14.7.1. Distribution by Industry Served
14.7.2. Distribution by Geography
14.7.3. Type of Modular Cleanrooms Offered

15. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS
15.1. Chapter Overview
15.2. Types of Continuous Manufacturing Technologies
15.3. Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics
15.3.1. Continuous Blending and Mixing Equipment
15.3.2. Continuous Granulating Equipment
15.3.3. Continuous Drying Equipment
15.3.4. Continuous Compression Equipment
15.3.5. Continuous Coating Equipment
15.3.6. Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment
15.3.7. Continuous Chromatography Equipment
15.3.8. Continuous Reactors / Bioreactors
15.3.9. Full Line Continuous Platforms
15.3.10. Process Analytical Technologies
15.3.11. Other Technologies
15.4. Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

16. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES
16.1. Chapter Overview
16.2. Key Strategies for the Adoption of Continuous Manufacturing Processes
16.2. 1. Phase I: Process Development and Implementation
16.2. 2. Phase II: Equipment / Technology Development and Installation
16.2. 3. Phase III: Facility / Plant Development and Establishment
16.2. 4. Phase IV: Product Development and Manufacturing

17. MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Overall, Continuous Manufacturing Market, 2020-2030
17.3.1. Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030
17.3.2. Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030
17.3.3. Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030
17.3.4. Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030
17.3.5. Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030
17.3.6. Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

17.4. Continuous Manufacturing Market for Small Molecule, 2020-2030
17.4.1. Distribution by Purpose of Manufacturing, 2020-2030
17.4.2. Distribution by Scale of Operation, 2020-2030
17.4.3. Distribution by Type of Continuous Manufacturing Related Service, 2020-2030
17.4.4. Distribution by Key Geographical Regions, 2020-2030

17.5. Continuous Manufacturing Market for Biologic, 2020-2030
17.5.1. Distribution by Purpose of Manufacturing, 2020-2030
17.5.2. Distribution by Scale of Operation, 2020-2030
17.5.3. Distribution by Type of Continuous Manufacturing Related Service, 2020-2030
17.5.4. Distribution by Key Geographical Regions, 2020-2030

18. CONCLUSION
18.1. Chapter Overview 
18.2. Key Takeaways

19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Zaiput Flow Technologies
19.2.1. Company Snapshot
19.2.2. Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer 

19.3. CONTINUUS Pharmaceuticals
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer

19.4. Snapdragon Chemistry
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Eric Fang, Chief Scientific Officer 

19.5. Enzene Biosciences
19.5.1. Company Snapshot
19.5.2. Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer 

19.6. Pfizer
19.6.1. Company Snapshot
19.6.2. Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development
19.7. University of Strathclyde
19.7.1. Company Snapshot
19.7.2. Interview Transcript: Ian Houson, Technical Project Manager

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 4.1 Continuous Drug Manufacturers: Distribution by Year of Establishment
Figure 4.2 Continuous Drug Manufacturers: Distribution by Company Size
Figure 4.3 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
Figure 4.4 Continuous Drug Manufacturers: Distribution by Scale of Operation
Figure 4.5 Continuous Drug Manufacturers: Distribution by Location of Headquarters
Figure 4.6 Continuous Drug Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Figure 4.7 Continuous Drug Manufacturers: Distribution by Type of Drug Molecule
Figure 4.8 Continuous Drug Manufacturers: Distribution by Type of Continuous Manufacturing Related Service
Figure 4.9 Continuous Drug Manufacturers: Distribution by Type of Dosage Form
Figure 4.10 Continuous Drug Manufacturers: Distribution by Year of Establishment and Type of Company Size
Figure 4.11 Continuous Drug Manufacturers: Distribution by Scale of Operation, Type of Continuous Manufacturing related Service Offered and Type of Dosage Form
Figure 4.12 Continuous Drug Manufacturers: Distribution by Location of Continuous Manufacturing Facility and Type of Drug Molecule Manufactured
Figure 5.1 AbbVie: Annual Revenues, 2014-2019 (USD Billion)
Figure 5.2 AbbVie Contract Manufacturing: Services Portfolio
Figure 5.3 Cambrex: Annual Revenues, 2014 – 9M 2019 (USD Million)
Figure 5.4 Cambrex: Services Portfolio
Figure 5.5 Thermo Fisher Scientific: Annual Revenues, 2014-2019 (USD Million)
Figure 5.7 SK biotek: Service Portfolio
Figure 6.1 Ajinomoto Bio-Pharma Services: Annual Revenues, FY 2015 - FY 2019 (JPY Billion)
Figure 6.2 Ajinomoto Bio-Pharma Service: Services Portfolio
Figure 6.3 Almac: Service Portfolio
Figure 6.4 Boehringer Ingelheim: Annual Revenues, 2014- H1 2019 (EUR Billion)
Figure 6.5 Boehringer Ingelheim BioXcellence: Service Portfolio
Figure 6.7 Hovione: Service Portfolio
Figure 6.8 Lonza: Annual Revenues, 2014-2019 (CHF Billion)
Figure 6.9 Lonza: Service Portfolio
Figure 7.1 Kaneka: Annual Revenues, FY 2014 – 9M 2019 (JPY Billion)
Figure 7.2 Kaneka: Service Portfolio
Figure 7.3 WuXi AppTec: Annual Revenues, 2015-2019 (RMB Million)
Figure 7.4 WuXi Biologics: Service Portfolio
Figure 7.5 STA Pharmaceuticals: Service Portfolio
Figure 8.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2019
Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2013-2019
Figure 8.4. Partnerships and Collaborations: Distribution by Type of Partnership, 2013-2015 and 2016-2019
Figure 8.5. Partnerships and Collaborations: Distribution by Scale of Operation
Figure 8.6. Partnerships and Collaborations: Distribution by Type of Drug Molecule
Figure 8.7. Partnerships and Collaborations: Distribution Type of Continuous Manufacturing Related Service
Figure 8.8. Partnerships and Collaborations: Distribution by Type of Dosage Form
Figure 8.9. Most Active Players: Distribution by Number of Partnerships
Figure 8.10. Partnerships and Collaborations: Regional Distribution
Figure 8.11. Partnerships and Collaborations: Intercontinental and Intracontinental
Figure 9.1. Recent Expansions: Cumulative Year-wise Trend, 2013- January 2020
Figure 9.2. Recent Expansions: Distribution by Type of Expansion
Figure 9.3. Recent Expansions: Distribution by Scale of Operation and Year of Expansion Figure 9.4.Recent Expansions: Distribution by Type of Drug Molecule
Figure 9.5. Recent Expansions: Distribution by Type of Continuous Manufacturing Related Service
Figure 9.6. Recent Expansions: Distribution by Type of Dosage Form
Figure 9.7. Most Active Players: Distribution by Number of Expansions
Figure 9.8. Recent Expansions: Intercontinental and Intracontinental Distribution
Figure 9.9. Recent Expansions: Regional Distribution
Figure 10.1 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Geographical Location
Figure 10.2 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Company Size (Range of Capacity)
Figure 10.3 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Company Size (in Metric Tonnes / Year)
Figure 10.4 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Purpose of Manufacturing (in Metric Tonnes / Year)
Figure 10.5 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Scale of Operation (in Metric Tonnes / Year)
Figure 10.6 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Headquarters (in Metric Tonnes / Year)
Figure 10.7 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Continuous Manufacturing Facilities (in Metric Tonnes / Year)
Figure 10.8 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Geographical Location
Figure 10.9 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Company Size (Range of Capacity)
Figure 10.10 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Company Size (in Kgs / Year)
Figure 10.11 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Purpose of Manufacturing (in Kgs / Year)
Figure 10.12 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Scale of Operation (in Kgs / Year)
Figure 10.13 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Headquarters (in Kgs / Year)
Figure 10.14 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
Figure 10.15 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Geographical Location
Figure 10.16 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Company Size (Range of Capacity)
Figure 10.17 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Company Size (in Kgs / Year)
Figure 10.18 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Purpose of Manufacturing (in Kgs / Year)
Figure 10.19 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Scale of Operation (in Kgs / Year)
Figure 10.20 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Headquarters (in Kgs / Year)
Figure 10.21 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
Figure 11.1 Academic Grant Analysis: Cumulative Year-wise Trend, 2014-2019
Figure 11.2 Academic Grant Analysis: Distribution by Activity Codes
Figure 11.3 Academic Grant Analysis: Year-wise Distribution by Leading Activity Codes
Figure 11.4 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 11.5 Academic Grant Analysis: Distribution by Focus Areas
Figure 11.6 Academic Grant Analysis: Distribution by Support Period
Figure 11.7 Popular Recipient Organizations: Distribution by States in the US 
Figure 11.8 Popular Recipient Organizations: Distribution by Number of Grants
Figure 11.9 Popular Recipient Organizations: Distribution by Amount Awarded
Figure 11.10 Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 11.11 Academic Grant Analysis: Distribution by Support Year and Funding Institute Centre
Figure 11.12 Academic Grant Analysis: Distribution by Funding Mechanism
Figure 11.13 Prominent Program Officers: Distribution by Number of Grants
Figure 12.1 Patent Portfolio: Distribution by Type of Patent
Figure 12.2 Patent Portfolio: Cumulative Year-wise Trend, till 2019
Figure 12.3 Patent Portfolio: Cumulative Year-wise Trend, till 2019 (for
Pharmaceutical and Biopharmaceutical Industry) 
Figure 12.4 Patent Portfolio: Distribution by Geography
Figure 12.5 Patent Portfolio: Distribution by CPC Symbols
Figure 12.6 Patent Portfolio: Distribution of CPC Symbols by Publication Year
Figure 12.7 Patent Portfolio: Emerging Focus Areas
Figure 12.8 Patent Portfolio: Distribution by Type of Applicant
Figure 12.9 Leading Industry Players: Distribution by Number of Patents
Figure 12.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 12.11 Patent Portfolio: Three-Dimensional Bubble Analysis
Figure 12.12 Patent Portfolio: Distribution by Patent Age, 2000-2019
Figure 12.13 Patent Portfolio: Distribution by Geography, Before 2014-2019
Figure 12.14 Patent Portfolio: Valuation Analysis
Figure 13.1 Continuous Manufacturing Initiatives: AbbVie
Figure 13.2 Continuous Manufacturing Initiatives: Amgen
Figure 13.3 Continuous Manufacturing Initiatives: Bristol-Myers Squibb
Figure 13.4 Continuous Manufacturing Initiatives: GlaxoSmithKline
Figure 13.5 Continuous Manufacturing Initiatives: Merck
Figure 13.6 Continuous Manufacturing Initiatives: Novartis
Figure 13.7 Continuous Manufacturing Initiatives: Pfizer
Figure 13.8 Continuous Manufacturing Initiatives: Roche
Figure 13.9 Continuous Manufacturing Initiatives: Sanofi
Figure 14.1 Modular Construction: Applications
Figure 14.2 Modular Construction: Processes Involved
Figure 14.3 Modular and Conventional Buildings: Construction Timelines
Figure 14.4 Modular Construction: Advantages
Figure 14.5 Modular Facility Manufacturers: Distribution by Geography
Figure 14.6 Modular Cleanroom Providers: Distribution by Geography
Figure 15.1 Type of Continuous Manufacturing Technologies: Hybrid vs Fully Integrated Continuous Technologies
Figure 15.2 Logo Landscape: Distribution of Technology / Equipment Providers by Number and Type of Equipment / Technology
Figure 16.1 Continuous Manufacturing: Key Strategies for the Adoption of Continuous Manufacturing Processes
Figure 16.2 Process Development and Implementation (Phase I): Distribution by Type of Strategies Adopted
Figure 16.3 Equipment / Technology Development and Installation (Phase II): Distribution by the Type of Strategies Adopted
Figure 16.4 Facility / Plant Development and Establishment (Phase III): Distribution by the Type of Strategies Adopted
Figure 16.5 Product Development and Manufacturing (Phase IV): Distribution by the Type of Strategies Adopted
Figure 17.1 Continuous Manufacturing, 2020-2030: Year-Wise Adoption Curve by Type of Molecule and Manufacturing Service (%)
Figure 17.2. Overall, Continuous Manufacturing Market, 2020-2030 (USD Million)
Figure 17.3. Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030 (USD Million)
Figure 17.4. Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 17.5. Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030 (USD Million)
Figure 17.6. Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030 (USD Million)
Figure 17.7. Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030 (USD Million)
Figure 17.8. Continuous Manufacturing Market: Distribution by Geographical Regions 2020-2030 (USD Million)
Figure 17.9 Continuous Manufacturing Market for Small Molecules: Distribution by Purpose of Manufacturing, 2020-2030 (USD Million)
Figure 17.10 Continuous Manufacturing Market for Small Molecule: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 17.11 Continuous Manufacturing Market for Small Molecule: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030 (USD Million)
Figure 17.12 Continuous Manufacturing Market for Small Molecule: Distribution by Key Geographical Regions, 2020-2030 (USD Million)
Figure 17.13 Continuous Manufacturing Market for Biologic: Distribution by Purpose of Manufacturing, 2020-2030 (USD Million)
Figure 17.14 Continuous Manufacturing Market for Biologic: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 17.15 Continuous Manufacturing Market for Biologic: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030 (USD Million)
Figure 17.16 Continuous Manufacturing Market for Biologic: Distribution by Key Geographical Regions, 2020-2030 (USD Million)

List Of Tables

Table 3.1 Comparison of Characteristics: Batch Manufacturing Technique and Continuous Manufacturing Technique
Table 4.1 List of Companies with Expertise in Continuous Drug Manufacturing
Table 4.2 Continuous Drug Manufacturers: Information on Location and Number of Continuous Drug Manufacturing Facilities
Table 4.3 Continuous Drug Manufacturers: Information on Type of Drug Molecule
Table 4.4 Continuous Drug Manufacturers: Information on Type of Continuous Manufacturing Related Service
Table 4.5 Continuous Drug Manufacturers: Information on Type of Dosage Form
Table 4.6 Continuous Drug Manufacturers: Distribution by Company Size and Location of Headquarters
Table 4.7 Continuous Drug Manufacturers: Information on Production Capacity
Table 5.1 AbbVie: Company Snapshot
Table 5.2 AbbVie Contract Manufacturing: Continuous Manufacturing Facilities
Table 5.3 AbbVie Contract Manufacturing: Continuous Manufacturing Capabilities
Table 5.4 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 5.5 Cambrex: Company Snapshot
Table 5.6 Cambrex: Continuous Manufacturing Facilities
Table 5.7 Cambrex: Continuous Manufacturing Capabilities
Table 5.8 Cambrex: Recent Developments and Future Outlook
Table 5.9 Patheon: Company Snapshot
Table 5.10 Patheon: Continuous Manufacturing Facilities
Table 5.11 Patheon: Continuous Manufacturing Capabilities
Table 5.12 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 5.13 SK biotek: Company Snapshot
Table 5.14 SK biotek: Continuous Manufacturing Facilities
Table 5.15 SK biotek: Continuous Manufacturing Capabilities
Table 5.16 SK biotek: Recent Developments and Future Outlook
Table 6.1 Ajinomoto Bio-Pharma Services: Company Snapshot
Table 6.2 Ajinomoto Bio-Pharma Services: Continuous Manufacturing Facilities
Table 6.3 Ajinomoto Bio-Pharma Services: Continuous Manufacturing Capabilities
Table 6.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 6.5 Almac: Company Snapshot
Table 6.6 Almac: Continuous Manufacturing Facilities
Table 6.7 Almac: Continuous Manufacturing Capabilities
Table 6.8 Almac: Recent Developments and Future Outlook
Table 6.9 Boehringer Ingelheim BioXcellence™: Company Snapshot
Table 6.10 Boehringer Ingelheim BioXcellence™: Continuous Manufacturing Facilities
Table 6.11 Boehringer Ingelheim BioXcellence™: Continuous Manufacturing Capabilities
Table 6.12 Boehringer Ingelheim BioXcellence™: Recent Developments and Future Outlook
Table 6.13 CordonPharma: Company Snapshot
Table 6.14 CordonPharma: Continuous Manufacturing Facilities
Table 6.15 CordonPharma: Continuous Manufacturing Capabilities
Table 6.16 CordonPharma: Recent Developments and Future Outlook
Table 6.17 Hovione: Company Snapshot
Table 6.18 Hovione: Continuous Manufacturing Facilities
Table 6.19 Hovione: Continuous Manufacturing Capabilities
Table 6.20 Hovione: Recent Developments and Future Outlook
Table 6.21 Lonza: Company Snapshot
Table 6.22 Lonza: Continuous Manufacturing Facilities
Table 6.23 Lonza: Continuous Manufacturing Capabilities
Table 6.24 Lonza: Recent Developments and Future Outlook
Table 7.1 Kaneka: Company Snapshot
Table 7.2 Kaneka: Continuous Manufacturing Facilities
Table 7.3 Kaneka: Continuous Manufacturing Capabilities
Table 7.4 Kaneka: Recent Developments and Future Outlook
Table 7.5 WuXi Biologics: Company Overview
Table 7.6 STA Pharmaceuticals: Company Overview
Table 7.7 WuXi Biologics: Continuous Manufacturing Facilities
Table 7.8 WuXi Biologics: Continuous Manufacturing Capabilities
Table 7.9 STA Pharmaceuticals: Continuous Manufacturing Facilities
Table 7.10 STA Pharmaceuticals: Continuous Manufacturing Capabilities
Table 7.11 WuXi Apptec: Future Outlook
Table 8.1 Continuous Manufacturing: List of Partnerships and Collaborations, 2013-2019
Table 8.2 Continuous Manufacturing: Information on Scale of Production, Type of Drug Molecule, Continuous Manufacturing Related Services and Type of Drug Product, 2013- 2019
Table 9.1 Continuous Manufacturing: List of Recent Expansions, 2013-January 2020
Table 9.2 Continuous Manufacturing: Information on Scale of Production, Type of Drug Molecule, Continuous Manufacturing Related Services and Type of Drug Product, 2013- January 2020
Table 10.1 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Average Capacity by Company Size (Sample Data Set)
Table 10.2 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Average Capacity by Company Size (Sample Data Set)
Table 10.3 Global, Overall Continuous Manufacturing Capacity for Biologics (Kgs / Year): Average Capacity by Company Size (Sample Data Set)
Table 11.1 Continuous Manufacturing: List of Academic Grants, 2014-2019
Table 12.1 Patent Portfolio: CPC Symbols
Table 12.2 Patent Portfolio: Most Popular CPC Symbols
Table 12.3 Patent Portfolio: List of Top CPC symbols
Table 12.4 Patent Valuation Analysis: Categorization based on Proprietary Scoring Criteria
Table 12.5 Patent Portfolio: Distribution by Number of Citations
Table 13.1 AbbVie: Partnered Initiatives
Table 13.2 AbbVie: In-House Initiatives
Table 13.3 Amgen: Partnered Initiatives
Table 13.4 Amgen: In-House Initiatives
Table 13.5 Bristol-Myers Squibb: Partnered Initiatives
Table 13.6 Bristol-Myers Squibb: In-House Initiatives
Table 13.7 GlaxoSmithKline: Partnered Initiatives
Table 13.8 GlaxoSmithKline: In-House Initiatives
Table 13.9 Merck: Partnered Initiatives
Table 13.10 Merck: In-House Initiatives
Table 13.11 Novartis: Partnered Initiatives
Table 13.12 Novartis: In-House Initiatives
Table 13.13 Pfizer: Partnered Initiatives
Table 13.14 Pfizer: In-House Initiatives
Table 13.15 Roche: Partnered Initiatives
Table 13.16 Roche: In-House Initiatives
Table 13.17 Sanofi: Partnered Initiatives
Table 13.18 Sanofi: In-House Initiatives
Table 14.1 List of Modular Facility Manufacturers
Table 14.2 Modular Facility Manufacturers: Information on Type of Industry Served
Table 14.3 Modular Facility Manufacturers: Modular Projects Executed / Undertaken
Table 14.4 Cleanrooms Classification Standards
Table 14.5 ISO and FED STD 209E: Cleanroom Classification
Table 14.6 List of Modular Cleanroom Providers
Table 14.7 Modular Cleanroom Providers: Information on Type of Industry Served
Table 14.8 Modular Cleanroom Providers: Information on Type of Modular Cleanroom Offered
Table 15.1 Technology and Equipment Providers: List of Continuous Blending and Mixing Equipment
Table 15.2 Technology and Equipment Providers: List of Continuous Granulating Equipment
Table 15.3 Technology and Equipment Providers: List of Continuous Drying Equipment
Table 15.4 Technology and Equipment Providers: List of Continuous Compression Equipment
Table 15.5 Technology and Equipment Providers: List of Continuous Coating Equipment
Table 15.6 Technologies and Equipment Providers: List of Continuous Filtration, Distillation and Centrifugation Equipment
Table 15.7 Technologies and Equipment Providers: List of Continuous Chromatography Equipment
Table 15.8 Technologies and Equipment Providers: List of Continuous Flow Reactors / Bioreactors
Table 15.9 Technology and Equipment Providers: List of Full Line Continuous Platforms
Table 15.10 Technology and Equipment Providers: List of Process Analytical Technologies
Table 15.11 Technology and Equipment Providers: List of Other Technologies
Table 18.1 Continuous Manufacturing Market: Key Takeaways
Table 19.1 Zaiput Flow Technologies: Key Highlights
Table 19.2 CONTINUUS Pharmaceuticals: Key Highlights
Table 19.3 Snapdragon Chemistry: Key Highlights
Table 19.4 Enzene Biosciences: Key Highlights
Table 19.5 Pfizer: Key Highlights
Table 19.6 University of Strathclyde: Key Highlights
Table 20.1 Continuous Drug Manufacturers: Distribution by Year of Establishment
Table 20.2 Continuous Drug Manufacturers: Distribution by Company Size
Table 20.3 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
Table 20.4 Continuous Drug Manufacturers: Distribution by Scale of Operation
Table 20.5 Continuous Drug Manufacturers: Distribution by Location of Headquarters
Table 20.6 Continuous Drug Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Table 20.7 Continuous Drug Manufacturers: Distribution by Type of Drug Molecule
Table 20.8 Continuous Drug Manufacturers: Distribution by Type of Continuous Manufacturing Related Service
Table 20.9 Continuous Drug Manufacturers: Distribution by Type of Dosage Form
Table 20.10 AbbVie: Annual Revenues, 2014–2019 (USD Billion)
Table 20.11 Cambrex: Annual Revenues, 2014-9M 2019 (USD Million)
Table 20.12 Thermo Fisher Scientific Patheon: Annual Revenues, 2014-2019 (USD Million)
Table 20.13 Ajinomoto Bio-Pharma Services: Annual Revenues, FY20154–FY2019 Revenue (JPY Billion)
Table 20.14 Boehringer Ingelheim: Annual Revenues, 2014- H1 2019, (EUR Billion)
Table 20.15 Lonza: Annual Revenues, 2014-2019 (CHF Billion)
Table 20.16 Kaneka: Annual Revenues, FY2014-9M 2019, (YENJPYJPY Billion)
Table 20.17 WuXi Apptec: Annual Revenues, 2015-2019 (RMB Million)
Table 20.18 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2019
Table 20.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.20 Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2013-2019
Table 20.21. Partnerships and Collaborations: Distribution by Type of Partnership, 2013-2015 and 2016-2019
Table 20.22 Partnerships and Collaborations: Distribution by Scale of Operation
Table 20.23 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Table 20.24 Partnerships and Collaborations: Distribution by Type of Continuous Manufacturing Related Service
Table 20.25 Partnerships and Collaborations: Distribution by Type of Dosage Form
Table 20.26 Most Active Players: Distribution by Number of Partnerships
Table 20.27 Partnerships and Collaborations: Regional Distribution
Table 20.28 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 20.29 Recent Expansions: Cumulative Year-wise Trend, 2013- January 2020
Table 20.30 Recent Expansions: Distribution by Type of Expansion
Table 20.31 Recent Expansions: Distribution by Type of Drug Molecule
Table 20.32 Recent Expansions: Distribution by Type of Continuous Manufacturing Related Service
Table 20.33 Recent Expansions: Distribution by Type of Dosage Form
Table 20.34 Most Active Players: Distribution by Number of Expansions
Table 20.35 Recent Expansions: Intercontinental and Intracontinental Distribution
Table 20.36 Recent Expansions: Regional Distribution
Table 20.37 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Company Size (in Metric Tonnes / Year)
Table 20.38 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Purpose of Manufacturing (in Metric Tonnes / Year)
Table 20.39 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Scale of Operation (in Metric Tonnes / Year)
Table 20.40 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Headquarters (in Metric Tonnes / Year)
Table 20.41 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Continuous Manufacturing Facilities (in Metric Tonnes / Year)
Table 20.42 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Company Size (in Kgs / Year)
Table 20.43 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Purpose of Manufacturing (in Kgs / Year)
Table 20.44 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Scale of Operation (in Kgs / Year)
Table 20.45 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Headquarters (in Kgs / Year)
Table 20.46 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
Table 20.47 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Company Size (in Kgs / Year)
Table 20.48 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Purpose of Manufacturing (in Kgs / Year)
Table 20.49 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Scale of Operation (in Kgs / Year)
Table 20.50 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Headquarters (in Kgs / Year)
Table 20.51 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
Table 20.52 Academic Grant Analysis: Cumulative Year-wise Trend, 2014-2019
Table 20.53 Academic Grant Analysis: Distribution by Activity Codes
Table 20.54 Academic Grant Analysis: Year-wise Distribution on Leading Activity Codes
Table 20.55 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 20.56 Academic Grant Analysis: Distribution by Support Period
Table 20.57 Popular Recipient Organizations: Distribution by Number of Grants
Table 20.58 Popular Recipient Organizations: Distribution by Amount Awarded (USD Million)
Table 20.59 Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 20.60 Academic Grant Analysis: Distribution by Support Year and Funding Institute Centre
Table 20.61 Academic Grant Analysis: Distribution by Funding Mechanism
Table 20.62 Prominent Program Officers: Distribution by Number of Grants
Table 20.63 Patent Portfolio: Distribution by Type of Patent
Table 20.64 Patent Portfolio: Cumulative Year-wise Trend, till 2019
Table 20.65 Patent Portfolio: Cumulative Year-wise Trend, till 2019 (Pharmaceutical and Biopharmaceutical Industry)
Table 20.66 Patent Portfolio: Distribution by Geography
Table 20.67 Patent Portfolio: Distribution of CPC Symbols by Publication Year (Before 2014-2019)
Table 20.68 Patent Portfolio: Distribution by Type of Applicant
Table 20.69 Leading Industry Players: Distribution by Number of Patents
Table 20.70 Leading Non-Industry Players: Distribution by Number of Patents
Table 20.71 Patent Portfolio: Distribution of Patents by Age, 2000-2019
Table 20.72 Patent Portfolio: Distribution of Patents by Geography, Before 2014-2019
Table 20.73 Continuous Manufacturing, 2020-2030: Year-Wise Adoption Curve by Type of Molecule and Manufacturing Service (%)
Table 20.74 Overall, Continuous Manufacturing Market, 2020-2030 (USD Million)
Table 20.75 Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030 (USD Million)
Table 20.76 Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Table 20.77 Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030 (USD Million)
Table 20.78 Continuous Manufacturing Market (Small Molecules and Biologics): Distribution by Type of Continuous Manufacturing Related Service, 2020-2030 (USD Million)
Table 20.79 Continuous Manufacturing Market (Small Molecules and Biologics): Distribution by Type of Dosage Form, 2020-2030 (USD Million)
Table 20.80 Continuous Manufacturing Market (Small Molecules and Biologics): Distribution by Key Geographical Regions, 2020-2030 (USD Million)
Table 20.81 Continuous Manufacturing Market for Small Molecule: Distribution by Purpose of Manufacturing, 2020-2030 (USD Million)
Table 20.82 Continuous Manufacturing Market for Small Molecule: Distribution by Scale of Operation, 2020-2030 (USD Million)
Table 20.83 Continuous Manufacturing Market for Small Molecule: Distribution by Type of Continuous Manufacturing Related Services, 2020-2030 (USD Million)
Table 20.84 Continuous Manufacturing Market for Small Molecule: Distribution by Key Geographical Regions, 2020-2030 (USD Million)
Table 20.85 Continuous Manufacturing Market for Biologic: Distribution by Purpose of Manufacturing, 2020-2030 (USD Million)
Table 20.86 Continuous Manufacturing Market for Biologic: Distribution by Scale of Operation, 2020-2030 (USD Million)
Table 20.87 Continuous Manufacturing Market for Biologic: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030 (USD Million)
Table 20.88 Continuous Manufacturing Market for Biologic: Distribution by Key Geographical Regions, 2020-2030 (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3P Biopharmaceuticals 
  2. Abbott
  3. AbbVie
  4. ABN Cleanroom Technology
  5. AC Immune
  6. Acasti Pharma
  7. ADC Biotechnology
  8. ADDvise Group
  9. ADMARES
  10. AES Clean Technology
  11. Aether
  12. Airgas
  13. Ajinomoto
  14. Albian Group
  15. Alconbury Weston
  16. Allied Cleanrooms
  17. Almac
  18. Alysophil
  19. AM Technology
  20. Amar chemistry
  21. American Cleanroom Systems
  22. Amgen
  23. AMPAC Fine chemicals
  24. AMRI
  25. Angelini Pharma
  26. Angstrom Technology 
  27. Arcinova
  28. AstraZeneca
  29. Asymchem
  30. Autichem
  31. AveXis
  32. Bassaire 
  33. Baxter
  34. Bayer
  35. BeiGene
  36. Bellen Chemistry
  37. Bigneat
  38. Biologics Modular
  39. Bioprocessing Technology Institute
  40. BiosanaPharma
  41. Bode Equipment 
  42. Boehringer Ingelheim
  43. Boehringer Ingelheim BioXcellence
  44. Bouygues Energies & Services
  45. Bristol-Myers Squibb
  46. Broad Sustainable Building
  47. Budapest University of Technology and Economics
  48. Caliber Biotherapeutics
  49. Cambrex
  50. Cell Culture Company
  51. Centillion technology
  52. Centre for Process Innovation
  53. Cerbios-Pharma
  54. Chemtrix BV
  55. China Construction Third Engineering Bureau
  56. ChromaCon
  57. ChromaTan
  58. CID Associates 
  59. Cipla
  60. CiTOS
  61. Clean Air Flow
  62. Clean Air Products
  63. Clean Air Technology
  64. Clean Rooms International
  65. Cleanrooms By United
  66. ClearSphere
  67. Clestra Cleanroom 
  68. Cleveland Clinic Lerner College of Medicine 
  69. Continuous Manufacturing and Advanced Crystallisation
  70. Commonwealth Scientific and Industrial Research Organisation
  71. CONITNUUS Pharmaceuticals
  72. Consort Medical
  73. Coperion
  74. CordenPharma
  75. Corning
  76. Dalton Pharma Services
  77. Debut Biotech
  78. DOTTIKON EXCLUSIVE SYNTHESIS
  79. DSM Pharmaceutical
  80. Durham University
  81. Eburon Organics
  82. EcoSynth
  83. Eli Lilly
  84. Envair Electrodyne
  85. Environmental Systems Corporation
  86. Enzene Biosciences
  87. ERTFLOW
  88. Esco Aster
  89. Evonik
  90. Farmhispania
  91. Fette Compacting
  92. Filtration Technology 
  93. Flowid
  94. FlowRHEX
  95. Fluor
  96. Foothills Systems
  97. FUJIFILM Diosynth Biotechnologies
  98. FutureChemistry
  99. G-CON Manufacturing
  100. GE Healthcare Life Sciences
  101. GEA
  102. Gebrüder Lödige Maschinenbau 
  103. GenCure
  104. Genentech
  105. Gerbig Cleanrooms
  106. Gericke
  107. Germfree
  108. Gilead
  109. Glatt
  110. GlaxoSmithKline
  111. Goodwin Biotechnology
  112. Grace
  113. HEMCO Corporation
  114. HEPAire Products Corporation
  115. Hermetel Oy
  116. Hodess Construction 
  117. Hosokawa Micron
  118. Hovione
  119. Huoshenshan Hospital
  120. Illinois Institute of Technology 
  121. IMA Active
  122. InnoSyn
  123. Instaspace
  124. Max Planck Institute of Molecular Cell Biology and Genetics
  125. Instituto Butantan
  126. IPM Technologies
  127. Jacobs Engineering Group
  128. Janssen Pharmaceuticals
  129. JHL Biotech
  130. Johnson & Johnson
  131. Johnson Matthey
  132. KABTech 
  133. Kaneka
  134. KeyPlants
  135. KinetiChem
  136. Kingspan
  137. Knowles Group
  138. Konkuk University
  139. KORSCH
  140. L.B. Bohle Maschinen+ Verfahren
  141. Lasco Services
  142. Liberty Industries
  143. Longden Company
  144. Lonza
  145. M+W Group
  146. Mach-Aire
  147. Magritek
  148. Massachusetts Institute of Technology
  149. Max Planck Institute
  150. MDI
  151. MECART
  152. Medichem
  153. Medicines Manufacturing Innovation Centre
  154. Merck
  155. Merit Holdings
  156. Mettler Toledo
  157. Michigan State University 
  158. Microflow CVO
  159. Microinnova
  160. Microzone Corporation
  161. Modular Cleanrooms 
  162. ModWave
  163. MRC Systems
  164. MTX Contracts
  165. Munson Machinery
  166. Mycenax
  167. National Cancer Institute
  168. National Center for Advancing Translational Sciences
  169. National Heart, Lung, and Blood Institute 
  170. National Institute for Innovation in Manufacturing Biopharmaceuticals
  171. National Institute of Allergy and Infectious Diseases
  172. National Institute of Dental and Craniofacial Research
  173. National Institute of Diabetes and Digestive and Kidney 
  174. National Institute of Environmental Health Sciences
  175. National Institute of General Medical Sciences
  176. National Institute of Neurological Disorders and Stroke
  177. National Partitions
  178. National University of Singapore
  179. Natrix Seperations
  180. New England Controls
  181. NGS Cleanroom Solutions
  182. Nicomac
  183. NiTech Solutions
  184. NJ Bio
  185. NNE
  186. Novartis
  187. Novasep
  188. Nuvonis Technologies
  189. OCTANORM 
  190. Onyx Scientific
  191. Pacific Environmental Technologies
  192. Pacific Scientific Energetic Materials
  193. Pall Corporation
  194. Parteco
  195. Patheon (Thermo Fischer Scientific)
  196. PaxVax
  197. Pentec Health
  198. Pfizer
  199. PharmaBlock Sciences
  200. Pharmadule Morimatsu
  201. Plascore
  202. Porsche Consulting 
  203. PortaFab
  204. Porta-King Building Systems
  205. Precision Cleanrooms 
  206. Precision NanoSystems
  207. Procos S.p.A.
  208. Proteaf Technologies (Intense process Technologies)
  209. Purdue University 
  210. QleanAir Scandinavia
  211. Repligen
  212. RITM
  213. Robert Bosch
  214. Robert Soper
  215. Roche
  216. Center for Structured Organic Particulate Systems
  217. Sanofi
  218. Sartorius
  219. Scarab Genomics
  220. Schering-Plough Corporation
  221. Seeq
  222. Sentinel Process Systems
  223. Servier 
  224. Siegfried
  225. Siemens
  226. Simplex Isolation Systems
  227. SK biotek
  228. Skender
  229. Snapdragon Chemistry
  230. Shelving + Rack Systems
  231. Starrco 
  232. STEELife
  233. Stefatos
  234. Sterling Pharma
  235. Stodec Products
  236. Stragen Pharma
  237. Strike Bio
  238. Syntegon (a subsidiary of Bosch Packaging Technology)
  239. Synthelia Organics
  240. Syrris
  241. Ted Thorsen Material Handling
  242. Telstar Life Science Solutions
  243. Terra Universal 
  244. Teruisi Pharmaceutical
  245. ThalesNano
  246. Florida State University Research Foundation
  247. TriboFilm Research
  248. United Partition Systems
  249. University of California
  250. University of Colorado
  251. University of Florida 
  252. University of Glasgow
  253. University of Illinois
  254. University of Nottingham
  255. University of Tennessee Health Science Center
  256. Vanguard Modular Building Systems
  257. Vapourtec
  258. Vernick & Associates
  259. Vertex Pharmaceuticals
  260. W.W. Cannon
  261. Weaver Technologies
  262. WH Partnership 
  263. Windmill Cardiovascular Systems
  264. Wuxi AppTec
  265. Xytel
  266. YMC Process Technologies
  267. Zaiput Flow Technologies
  268. Zeton

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com